Navigation Links
Stem cell study offers hope for Parkinson's patients

Scientists have for the first time generated stem cells from one of the most rapidly progressing forms of Parkinson's disease.

The development will help research into the condition as it will enable scientists to model the disease in the laboratory to shed light on why certain nerve cells die.

Scientists, funded with a 300,000 grant from the charity Parkinson's UK, took skin samples from a patient diagnosed with one of the most progressive types of Parkinson's.

The research, led by the University of Edinburgh in collaboration with UCL (University College London), then used these skin cells to generate brain nerve cells affected by the disease.

The ability to generate these nerve cells will make it easier to monitor the effectiveness of potential new drugs that could slow or halt progress of the condition.

The aim would be to find drugs that can prevent the death of these key cells known as neurons which break down as a result of Parkinson's.

Dr Tilo Kunath, of the University of Edinburgh's Medical Research Council Centre for Regenerative Medicine, said: "Current drugs for Parkinson's alleviate symptoms of the condition. Modelling the disease in a dish with real Parkinson's neurons enables us to test drugs that may halt or reverse the condition.

"This study provides an ideal platform to gain fresh insight into the condition, and opens a new area of research to discover disease-modifying drugs."

The neuron cells were generated from a patient with a form of Parkinson's that progresses rapidly and can be diagnosed in people in their early 30s.

People with this form of Parkinson's have twice as many of the genes that produce a protein alpha synuclein compared with the general population.

Although this form of Parkinson's is rare the protein involved is linked to virtually all types of the disease.

Dr Michael Devine, of the UCL Institute of Neurology said, "Understanding such a progressive form of the disease will give us insight into different types of Parkinson's. As this type of Parkinson's progresses rapidly it will also make it easier to pick up the effects of drugs tested to prevent nerve cells targeted by the disease from dying."

The research was published in the journal Nature Communications.

Dr Kieran Breen, Director of Research and Development at Parkinson's UK, said: "Although the genetic mutation that leads to this progressive form of Parkinson's is rare this exciting study has the potential to bring about a huge breakthrough in Parkinson's research.

"This is just the kind of innovative research that Parkinson's UK is committed to funding as we move closer to a cure."


Contact: Tara Womersley
University of Edinburgh

Related biology technology :

1. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
2. Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
3. Microbial study reveals sophisticated sensory response
4. BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
5. New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
7. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
8. As New Data Wave Begins, a Gene Study in One Disease Discovers Mutations in an Unrelated Disease
9. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
10. Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds
11. Diesel fumes pose risk to heart as well as lungs, study shows
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that ... 2015 at 11:00 a.m. Israel time, at the ... Yigal Allon Street, 36 th Floor, Tel Aviv, Israel ... Paneth and Izhak Tamir to the Board of Directors; ... external directors; , approval of an amendment to certain terms of ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):